14 years have passed since the Biologics Price Competition and Innovation Act was signed into law, and more than a year since Amgen’s Amjevita launched, the first in a string of nine Humira biosimilars. In this retrospective, industry stakeholders will assess the trends, market uptake, and lessons learned from both the Humira and non-Humira biosimilar launches and lawsuits, offering strategies for designing forward-thinking portfolio strategies. Topics of discussion include:

• Exploring which biosimilars have seen “successful” market uptake across product class, applications, and geography
• Reviewing the Adalimumab BPCIA biosimilars and identifying market dynamics, pricing strategies, and other factors influencing uptake disparities
• Assessing why the higher-priced Amjevita saw higher uptake than the lower-priced Amjevita
• Assessing the impact of interchangeable status on biosimilar uptake
• Reflecting on approved and marketed biosimilars while looking ahead and considering clinical insights, manufacturing needs, pricing and dosages for pipeline development